CMV Clinical Trial
Official title:
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients
NCT number | NCT04017962 |
Other study ID # | 19-174 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 19, 2019 |
Est. completion date | July 2024 |
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
Status | Recruiting |
Enrollment | 106 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Age >/= 12 years (any weight) - Have received allogenic HCT - Have received preemptive therapy for clinically significant CMV infection post-HCT and have completed preemptive therapy no longer than 7 days prior to enrollment. Preemptive treatment includes ganciclovir, valganciclovir, foscarnet or cidofovir. Clinically significant CMV infection is defined as CMV viremia requiring preemptive therapy or CMV EOD. Patients who have received LTV prophylaxis prior to onset of clinically significant CMV infection prior to enrollment (see also exclusion criteria below). - Have one or more risk factors for recurrent CMV infection: 1. Human leukocyte antigen (HLA) mismatch - HLA-related (sibling) donor with at least one mismatch at the HLA-A, -B or -DR gene loci - Haploidentical donor - Unrelated donor with at least one mismatch at the HLA-A, -B, -C or -DRC1gene loci, or - Cord blood as stem cell source 2. Acute or chronic GVHD requiring either topical steroids for gastrointestinal GVHD and/or systemic steroid treatment (>/= 1mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 14 days prior to enrollment 3. T-cell-depleted allograft ex-vivo or in-vivo T-cell depleting agents including but not limited to ATG, alemtuzimab and post HCT cyclophosphamide. - For adult patients, able to provide written consent and complete the informed consent. For patients under 18 years, the patient's parent(s) or legal guardian(s) must provide informed consent and the patient must provide written assent to participation in the study. - Willing and able to comply with trial instructions and requirements - Male and female patients of childbearing potential must be willing to use a highly effective method of contraception for the course of the study. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient. Subject eligibility criteria for the observational cohort: - Age 18 years or older - First allogenic peripheral blood or marrow HCT - LTV prophylaxis starting <30 days post HCT and given for at least 6 weeks Exclusion Criteria: - Clinically significant CMV infection present at enrollment - Breakthrough CMV infection while on primary LTV prophylaxis (unless patient non-adherent or unable to adequately absorb letermovir or documented resistance to LTV. - Glomerular filtration rate (GFR) </= mL/min/1.73m^2(equivalent to creatinine clearance </=10 mL/min) - Severe hepatic impairment - Routine use of high-dose acyclovir (doses of > 800 mg twice daily), valacyclovir (doses of > 500mg twice daily), or famciclovir (doses > 500mg/day) for varicella zoster virus (VZV)/herpes simplex virus prophylaxis; limited treatment courses at higher doses for VZV infections are permissible if treatment duration dose not exceed 14 days total. Short courses of IV cidofovir for adeno virus (ADV) are permissible - Suspected or known hypersensitivity to active or inactive ingredients of LTV formulations - Patients treated with a medication whose administration with LTV is ontraindicated and whose discontinuation is not possible. Contraindicated medications include pimozide, ergot alkaloids and pitavastatin or simvastatin when co-administered with cyclosporine. - Imminent demise (expected survival <6 weeks) - Documented positive result for human immunodeficiency virus antibody (HIV-Ab) or for hepatitis C virus antibody (HCV-Ab) with detectable HCV RNA, or hepatitis B surface antigen (HBsAg) at any time prior to HCT - Need for mechanical ventilation and/or vasopressor support at the time of enrollment - Pregnancy or breastfeeding - Plans to conceive or father children within the projected duration of the trial - History of current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or would place the subject at undue risk as judged by the investigator, such that it is not in the best interest of the subject to participate in this study. - The following antivirals are allowed up to the listed dose limits: - Acyclovir up to 800 mg twice daily - Valacyclovir up to 500 mg twice daily - Famciclovir up to 500 mg/day for VZV/HSV prophylaxis; limited treatment courses at higher doses for VZV infections are permissible if treatment duration does not exceed 14 days total. - Short courses of IV cidofovir for ADV (up to two doses) Exclusion criteria for observational cohort: - Clinically significant CMV infection during the 100 days following HCT. Clinically significant CMV infection defined as either CMV viremia requiring preemptive therapy with CMV antivirals or CMV end organ disease (EOD) - Grade 3-4 GVHD - Cord blood as cell source for HCT - Treatment with systemic steroids (>0.5mg/kg for 2 weeks or longer) within 3 weeks prior to enrollment |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Merck Sharp & Dohme LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of breakthrough clinically significant Cytomegalovirus (CMV) infection by week 14 | up to 24 weeks from time of study treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
Completed |
NCT02324244 -
CMV Intensive Care Units
|
N/A | |
Enrolling by invitation |
NCT06263218 -
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
|
||
Recruiting |
NCT04934527 -
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
|
Phase 2 | |
Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06341686 -
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
|
Phase 3 | |
Recruiting |
NCT02136797 -
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Terminated |
NCT02843880 -
Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study
|
N/A | |
Recruiting |
NCT04278547 -
Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response
|
Phase 4 | |
Recruiting |
NCT06021210 -
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
|
Phase 2 | |
Active, not recruiting |
NCT01633476 -
CMV Modulation of the Immune System in ANCA-associated Vasculitis
|
Phase 2 | |
Suspended |
NCT02988258 -
Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT
|
Phase 1 | |
Recruiting |
NCT03159364 -
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
|
Phase 1/Phase 2 | |
Recruiting |
NCT05089838 -
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
|
Phase 1 | |
Enrolling by invitation |
NCT05656599 -
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
|
||
Completed |
NCT02985775 -
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02083731 -
MSC for Treatment of CMV Infection
|
Phase 2 | |
Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
Recruiting |
NCT03798301 -
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
|
Phase 1 | |
Completed |
NCT02550639 -
Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant
|
Phase 4 |